China: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
China’s Rise As A Global Biopharma Innovation Hub: Navigating Trends, Opportunities, And Evolving Deal Structures
China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato
Global Healthcare
W
WilmerHale
Article
China Revises Good Clinical Practice Rules
China's revised Good Clinical Practice for Drug Trials took effect on 1 September 2026, fundamentally reshaping the regulatory landscape for clinical trials by aligning domestic requirements with ICH E6(R3) standards. The new framework introduces streamlined regulations spanning just 54 articles across six chapters, while establishing comprehensive data governance requirements and clarifying ultimate accountability for sponsors, principal investigators, and clinical trial institutions. Companies conducting
China Healthcare
B
Buren
Article
APEC Holds High-Level Policy Dialogue On Agricultural Biotechnology
The Asia-Pacific Economic Cooperation held a High-Level Policy Dialogue on Agricultural Biotechnology in Dalian, China, where participants explored how genome technologies are transforming food production across the region. Experts demonstrated innovations ranging from fish bred with fewer bones to rice varieties designed for diabetic populations, while addressing the critical challenge of public perception and regulatory frameworks. The dialogue emphasized science-based regulation and consumer education as
China Healthcare
BC
Bergeson & Campbell
Article
HHS Launches Operation TrialBlazer To Advance US Clinical Research Leadership
The US Department of Health and Human Services has launched Operation TrialBlazer to address China's growing dominance in clinical research and restore American leadership in biomedical innovation. As Chinese clinical trials now surpass US trials in both speed and volume, this comprehensive initiative aims to modernize regulatory processes, reduce administrative burdens, and reverse the trend of research investment flowing overseas.
China Healthcare
SR
McDermott Will & Schulte
See more
Article
APEC Holds High-Level Policy Dialogue On Agricultural Biotechnology
The Asia-Pacific Economic Cooperation held a High-Level Policy Dialogue on Agricultural Biotechnology in Dalian, China, where participants explored how genome technologies are transforming food production across the region. Experts demonstrated innovations ranging from fish bred with fewer bones to rice varieties designed for diabetic populations, while addressing the critical challenge of public perception and regulatory frameworks. The dialogue emphasized science-based regulation and consumer education as
China Healthcare
BC
Bergeson & Campbell
See more
Article
China’s Rise As A Global Biopharma Innovation Hub: Navigating Trends, Opportunities, And Evolving Deal Structures
China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato
Global Healthcare
W
WilmerHale
See more
Article
China Revises Good Clinical Practice Rules
China's revised Good Clinical Practice for Drug Trials took effect on 1 September 2026, fundamentally reshaping the regulatory landscape for clinical trials by aligning domestic requirements with ICH E6(R3) standards. The new framework introduces streamlined regulations spanning just 54 articles across six chapters, while establishing comprehensive data governance requirements and clarifying ultimate accountability for sponsors, principal investigators, and clinical trial institutions. Companies conducting
China Healthcare
B
Buren
Article
特殊疾病医疗期延长规则:236号文的适用现状
原劳动部1995年发布的《关于贯彻〈企业职工患病或非因工负伤医疗期规定〉的通知》(劳部发〔1995〕236号)第二条规定:“根据目前的实际情况,对某些患特殊疾病(如癌症、精神病、瘫痪等)的职工,在24个月内尚不能痊愈的,经企业和劳动主管部门批准,可以适当延长医疗期”。该条款的立法&
China Employment
AB
AnJie Broad Law Firm
See more